Welcome to our dedicated page for Silo Pharma news (Ticker: $SILO), a resource for investors and traders seeking the latest updates and insights on Silo Pharma stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Silo Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Silo Pharma's position in the market.
Rhea-AI Summary
Silo Pharma, Inc. (Nasdaq: SILO) announced plans to initiate a dose-ranging study of its targeted prophylactic treatment SPC-15 for the treatment of post-traumatic stress disorder (PTSD). The study will identify the maximum tolerated intranasal dose of the drug and pharmacokinetic in small animals to determine the therapeutically relevant dose range. Collaboration with AmplifyBio, Silo Pharma’s contract research organization (CRO) partner, will conduct a non-GLP study including single ascending dose evaluation and a 7-day repeat intranasal dose toxicity and pharmacokinetic study. The final validation report is expected in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.65%
Tags
-
Rhea-AI Summary
Silo Pharma plans to conduct a human factor study for its targeted prophylactic treatment SPC-15 for PTSD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.25%
Tags
-
Rhea-AI Summary
Silo Pharma plans to submit a pre-IND application to the FDA in Q1 2024 for its SPC-15 intranasal prophylactic for anxiety and PTSD. The company's pre-clinical data show additive benefits in combating stress-induced pathophysiology. Silo Pharma is working with Kymanox for regulatory support and plans to file a pre-IND meeting request with the FDA in early 2024. SPC-15 utilizes metabolic biomarker profiling to inform treatment and prevention of stress-related disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.76%
Tags
Rhea-AI Summary
Silo Pharma plans to submit an IND application for SPC-15 to the FDA in Q1 2024, pending positive results from in vitro lab tests on its selected delivery mechanism.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Silo Pharma, Inc. (SILO) has announced a partnership with Clarivate™ to manage its expanding intellectual property (IP) portfolio. The agreement includes the monitoring, maintenance, and strategic expansion of the Company's IP assets and technology rights, aiming to support pipeline development and reinforce protection for novel assets. Silo Pharma focuses on merging traditional therapeutics with psychedelic research and has acquired IP and technology rights through collaborations with leading universities and researchers. The company currently holds 3 issued and provisional patents, with additional patent applications pending. Year-to-date, Silo Pharma has been awarded 3 new patents and one patent extension, supporting its planned Investigational New Drug (IND) package submission to FDA for SP-26 and the use of central nervous system (CNS) homing peptides to treat Alzheimer's disease and dementia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2%
Tags
-
Rhea-AI Summary
Silo Pharma advances formulation development for therapeutic drug SPC-15, in discussions with potential delivery partners
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.68%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Silo Pharma, Inc. has been granted a new patent by the USPTO for their drug SPU-21, a peptide-guided anti-arthritis drug. The patent expands the company's intellectual property and technology rights portfolio, allowing them to selectively target inflamed synovial tissue. The drug has shown promise in inhibiting arthritic progression in preclinical animal models. Silo Pharma plans to use the drug for the development of fusion imaging molecules and nanoparticles to study arthritic pathogenesis. The market for rheumatoid arthritis drugs in the US is expected to reach $63 billion by 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
-
Rhea-AI Summary
Silo Pharma announces research and development agreement for ketamine implant to treat fibromyalgia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.26%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.84%
Tags
Silo Pharma, Inc.
Nasdaq:SILO
SILO Rankings
SILO Stock Data
4.78M
2.54M
6.35%
5.65%
2.16%
Securities and Commodity Exchanges
Finance and Insurance
United States of America
SARASOTA
About SILO
silo pharma inc. (nasdaq: silo), a developmental stage biopharmaceutical company, is focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as post-traumatic stress disorder, fibromyalgia, alzheimer’s disease, parkinson’s disease, and other rare neurological disorders. silo’s mission is to identify assets to license and fund research that the company believes will be transformative to the wellbeing of patients and the health care industry. silo is committed to developing innovative solutions to address a variety of underserved conditions. combining silo’s resources with world-class medical research partners, the company looks to make significant advances in the medical and psychedelic space. silo works to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization.